RT Journal Article
T1 Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
A1 Slamon, D J
A1 Neven, P
A1 Chia, S
A1 Jerusalem, G
A1 De Laurentiis, M
A1 Im, S
A1 Petrakova, K
A1 Valeria Bianchi, G
A1 Martín, M
A1 Nusch, A
A1 Sonke, G S
A1 De la Cruz-Merino, L
A1 Beck, J T
A1 Ji, Y
A1 Wang, C
A1 Deore, U
A1 Chakravartty, A
A1 Zarate, J P
A1 Taran, T
A1 Fasching, P A
YR 2021
FD 2021-08-16
LK https://hdl.handle.net/10668/27558
UL https://hdl.handle.net/10668/27558
LA en
DS RISalud
RD Apr 6, 2025